Elanco Animal Health Inc (NYSE: ELAN)’s stock price has plunge by -0.12relation to previous closing price of 12.08. Nevertheless, the company has seen a 0.37% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-27 that Hunter, Trooper, Scrappy and Buckaroo find zen by using Zenrelia Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) GREENFIELD, Ind., Jan. 27, 2025 /PRNewswire/ — Scratching, rubbing, chewing, licking.
Is It Worth Investing in Elanco Animal Health Inc (NYSE: ELAN) Right Now?
Elanco Animal Health Inc (NYSE: ELAN) has a price-to-earnings ratio of 29.53x that is above its average ratio. Additionally, the 36-month beta value for ELAN is 1.41. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for ELAN is 486.97M and currently, short sellers hold a 3.12% ratio of that float. The average trading volume of ELAN on January 27, 2025 was 4.49M shares.
ELAN’s Market Performance
ELAN’s stock has seen a 0.37% increase for the week, with a 1.73% rise in the past month and a -3.56% fall in the past quarter. The volatility ratio for the week is 2.51%, and the volatility levels for the past 30 days are at 3.11% for Elanco Animal Health Inc The simple moving average for the past 20 days is 1.22% for ELAN’s stock, with a -14.35% simple moving average for the past 200 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with UBS repeating the rating for ELAN by listing it as a “Buy.” The predicted price for ELAN in the upcoming period, according to UBS is $18 based on the research report published on December 09, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $14. The rating they have provided for ELAN stocks is “Market Perform” according to the report published on December 02nd, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to ELAN, setting the target price at $15 in the report published on September 19th of the previous year.
ELAN Trading at -3.21% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.82% of loss for the given period.
Volatility was left at 3.11%, however, over the last 30 days, the volatility rate increased by 2.51%, as shares surge +1.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.56% lower at present.
During the last 5 trading sessions, ELAN rose by +0.25%, which changed the moving average for the period of 200-days by -21.09% in comparison to the 20-day moving average, which settled at $11.92. In addition, Elanco Animal Health Inc saw -0.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELAN starting from Harrington Michael J, who purchase 3,500 shares at the price of $14.85 back on Aug 22 ’24. After this action, Harrington Michael J now owns 81,094 shares of Elanco Animal Health Inc, valued at $51,974 using the latest closing price.
Simmons Jeffrey N, the PRESIDENT, CEO AND DIRECTOR of Elanco Animal Health Inc, purchase 100,000 shares at $13.01 during a trade that took place back on Aug 12 ’24, which means that Simmons Jeffrey N is holding 145,000 shares at $1,300,610 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.49 for the gross margin
The net margin for Elanco Animal Health Inc stands at 0.05. The total capital return value is set at 0.02. Equity return is now at value 3.24, with 1.48 for asset returns.
Based on Elanco Animal Health Inc (ELAN), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is 0.86.
Currently, EBITDA for the company is -224.0 million with net debt to EBITDA at 2.78. When we switch over and look at the enterprise to sales, we see a ratio of 2.21. The receivables turnover for the company is 4.93for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.55.
Conclusion
In conclusion, Elanco Animal Health Inc (ELAN) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
